Y-90 With Durvalumab/Gem/Cis in Intrahepatic Cholangio

This study tests a combination of treatments for people with intrahepatic cholangiocarcinoma (bile duct cancer that starts inside the liver) that cannot be surgically removed. The combination includes a targeted internal radiation treatment called Y-90 radioembolization, plus immunotherapy (durvalumab), and chemotherapy (gemcitabine and cisplatin). **You may be eligible if...** - You are 18 or older - You have a confirmed diagnosis of advanced or spreading bile duct cancer (intrahepatic cholangiocarcinoma) - You have at least one measurable liver tumor - Your overall health is adequate (ECOG 0–1) - Your body weight is above 30 kg - Your blood counts, kidney function, and other lab values are within acceptable ranges - You have a life expectancy of at least 12 weeks **You may NOT be eligible if...** - Your cancer is not located inside the liver - Your overall health is too poor to receive this intensive combination treatment - Your blood or organ function is significantly impaired Talk to your doctor to see if this trial is right for you.